Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.7% – Time to Sell?

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) were down 6.7% during mid-day trading on Friday . The stock traded as low as $42.86 and last traded at $42.86. Approximately 150,856 shares changed hands during trading, a decline of 74% from the average daily volume of 586,785 shares. The stock had previously closed at $45.94.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on KYMR shares. Wells Fargo & Company boosted their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Truist Financial restated a “buy” rating and issued a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Oppenheimer upped their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Monday, September 9th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.21.

Kymera Therapeutics Stock Performance

The company has a market cap of $2.72 billion, a P/E ratio of -17.93 and a beta of 2.21. The business’s 50-day moving average price is $47.17 and its 200 day moving average price is $41.68.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics’s revenue was down 20.9% on a year-over-year basis. During the same period last year, the business posted ($0.90) EPS. Equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Pamela Esposito sold 13,500 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its stake in shares of Kymera Therapeutics by 18.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock worth $254,548,000 after purchasing an additional 996,300 shares during the period. FMR LLC increased its position in Kymera Therapeutics by 5.8% during the 3rd quarter. FMR LLC now owns 5,109,141 shares of the company’s stock worth $241,816,000 after buying an additional 282,301 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Kymera Therapeutics by 19.2% during the first quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after buying an additional 769,486 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Kymera Therapeutics by 7.2% in the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock valued at $218,587,000 after acquiring an additional 308,954 shares during the period. Finally, Avoro Capital Advisors LLC grew its stake in shares of Kymera Therapeutics by 3.0% in the first quarter. Avoro Capital Advisors LLC now owns 3,888,888 shares of the company’s stock valued at $156,333,000 after acquiring an additional 113,888 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.